Vizex Investments Ltd
financial consultations

Last news

Long term recommendation - Immune Pharmaceuticals (NASDAQ.IMNP)

Feb 04, 2018 2
Febryary 4th. We are starting coverage…

Transenterix announces 1st US sale

Nov 13, 2017 23
November 13th. Transenterix Inc…

Long term recommendation - Immune Pharmaceuticals (NASDAQ.IMNP)

We are starting our coverage of a micro size biotech company -- Immune Pharmaceuticals on February 4th 2018.

 

On February 4th 2018 market capitalization of the company is 10 million dollars.  The PPS is 0,48$.

 

The company is a clinical stage biotech with their flagship drug named Bertilimumab.  Bertilimumab is a fullu human monoclonal antibody that an potentially be used in a number of indications.

 

There are two Phase 2 trials ongoing right now.  One is an open label study in Bullous Pemphigoid - a severe skin disease that affect people over 60 years of age.  There are no existing treatments besides steroids that do severe damage to the body.  Mortality numbers among people diagnosed with Bullous pemphigoid two fold exceed those numbers among people not affected with the disease.  There have to be from 10 to 15 patients enrolled for the study.  Currently the company reports of 9 people enrolled by now.  The company have presented preliminary results on the first 6 patients and they showed a 85% average reduction of the disease symptoms, also the steroids injections were tapered almost to zero while taking Bertilimumab, and the drug has shown excellent safety and tolerability.

 

The company intends to complete enrollment for the study in Q1-Q2 2018 and to end the study in mid 2018.  After the study completion Immune is planning to have discussions with the FDA to obtain permission to start a Phase 3 study after which an application can be submitted to the FDA for commercial sales approval.

 

The market size in Bullous pemphigold is estimated as $500 million a year.

 

Another indication in which the other ongoing Phase 2 continues is Ulcerative Colitis - an inflammatory disease of the bowel.  There are 25 patients enrolled of 42 planned.  The company plans to release the results of the study by the end of 2018.

 

The market size in Ulcerative Colitis is over $1 billion a year.

 

The company has recently done a financing round that brout $18 million on the company balance sheet that seems to be enough to cover all costs related to the above mentioned trials

 

Besides that Immune has a wholly owned subsidiary named Cytovia oncology which is about to be spun off.  Shares of Cytovia are planned to be distributed to existing Immune shareholders as dividends.  

 

Cytovia holds the rights to a drug named Ceplene that is used for treatment of leukemia.  The drug is approved for commercial sales in the E.U. and has only one Phase 3 left to do before it can be apllied to the U.S. FDA for approval in the U.S.

 

 

Short term investment recommendation -- Apogee Enterprises (NASDAQ:APOG)

June 18th.  Apogee Enterprises, Inc. is engaged in the design and development of glass solutions for enclosing commercial buildings and framing art. The Company operates through four segments: Architectural Glass, Architectural Services, Architectural Framing Systems and Large-Scale Optical Technologies (LSO). The Architectural Glass segment fabricates coated glass used in customized window and wall systems. The Architectural Services segment designs, engineers, fabricates and installs the walls of glass, windows and other curtainwall products making up the outside skin of commercial and institutional buildings. The Architectural Framing Systems segment designs, engineers, fabricates and finishes the aluminum frames used in customized aluminum and glass window, curtainwall, storefront and entrance systems. The Large-Scale Optical Technologies segment manufactures glass and acrylic products for the custom picture framing and fine art markets.

 

On June 19th the shares could be bought at $56

 

On June 22nd the shares could be sold at 59$

 

Investors profit 5,2%

 

The recommendation is no longer valid

Short term investment recommendation -- Embotelladora Andina SA (NYSE:AKO.B)

June 4th  Embotelladora Andina S.A. (Andina) is a bottler of Coca-Cola trademark beverages in Latin America. The Company operates in four segments: Chile, Brazil, Argentina and Paraguay. It produces and distributes fruit juices, other fruit-flavored beverages and mineral and purified water in Chile, Argentina and Paraguay under trademarks owned by The Coca-Cola Company. The Company produces, markets and distributes the Coca-Cola trademark beverages and brands licensed from third-parties throughout its franchise territories. It manufactures polyethylene terephthalate (PET) bottles primarily for its own use in the packaging of Coca-Cola soft drinks in Chile and Argentina. In Brazil, it produces tea and juices for Leao Alimentos e Industria Ltda. It also distributes non-carbonated beverages in Brazil, such as tea, fruit juices, energy drinks, sport drinks and waters. It distributes beer in Brazil under the brands Amstel, Bavaria, Birra Moretti, Dos Equis (XX), Edelweiss, Heineken and Kaiser.

 

On June 5th the shares could be bought at 24.5$

 

On June 6th the shares could be sold at 25.78$

 

Investors profit 5.2%

 

The recommendation is no longer valid

Вайзекс Инвестментс ООД © 2015 | Всички права запазени